Evaluation of Exufiber Ag+ and Other Gelling Fibre Dressings
Launched by MOLNLYCKE HEALTH CARE AB · Aug 14, 2017
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Signed Informed Consent Form
- • Both gender ≥ 18 years old
- • From Medium to High exuding wound
- Exclusion Criteria:
- • Known allergy or hypersensitivity to any of the treatment dressings
- • Pregnant or lactating females
- • Subjects with a target wound that is ≤1 cm2
- • Subjects with a target wound that is a full thickness burn
- • Subjects with a target wound that is a full thickness pressure ulcer
- • Subjects with known immunodeficiency
- • Subject taking systemic antibiotics for wound infection
- • Subject were the target wound is located on an infected limb interfered by minimal blood flow in the opinion of the investigator
- • Subject with a target wound with unexplored enteric fistula
- • Subjects who in the opinion of the investigator, will have problems following the protocol
- • Subjects needing treatment with oxidizing agents such as hypochlorite solutions or hydrogen peroxide
- • Previously enrolled in the present investigation
- • Inclusion in other ongoing investigations at present that would preclude the subject from participating in this investigation as judged by the investigator
- • Involvement in the planning and conduct of the clinical investigation
About Molnlycke Health Care Ab
Mölnlycke Health Care AB is a global medical solutions company specializing in the development and manufacturing of innovative wound care and surgical products. With a strong commitment to enhancing patient outcomes, Mölnlycke combines extensive clinical expertise with advanced technology to deliver high-quality medical devices and solutions. The company operates with a focus on sustainability and collaboration with healthcare professionals, ensuring that their products meet the evolving needs of patients and healthcare systems worldwide. Through rigorous clinical trials and research, Mölnlycke continues to advance the field of healthcare, aiming to improve healing processes and promote patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampa, Florida, United States
Miami, Florida, United States
San Francisco, California, United States
Miami, Florida, United States
Lake Success, New York, United States
Glendale, Arizona, United States
Boise, Idaho, United States
Toledo, Ohio, United States
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Hadar Lev-Tov, MD, MAS
Principal Investigator
University of Miami
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials